Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of cefiderocol versus meropenem for hospital-acquired and ventilator-associated bacterial pneumonia
MOH_2018-03-20_002268Phase 3Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cefiderocol in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and bacterial pneumonia (2 arms), sponsored by Shionogi & Co., Ltd. Started Jul 2017; status: active, not recruiting.
02
Drugs
cefiderocol
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)bacterial pneumonia
Beyond the preview
Go deeper on MOH_2018-03-20_002268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-20_002268.